TRIUS THERAPEUTICS – Partnering or Buy Out = Upside

Date: 2015-07

Positive top line data of Tedizolid (oral/IV, 2nd-generation oxazolidinone, PhIII, Acute Bacterial Skin and Skin Structure Infections – ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA and ME rights) from 2nd pivotal PhIII study (ESTABLISH 2, Table 1A/1B) increases the probability of approval by 1H14 in US in ABSSSI indication. We expect Tedizolid to achieve switching from Zyvox (intolerant, deep tissue infections where long term treatment is required – pulmonary setting etc) and vancomycin (non-responsive and renal impaired). Partnership/Acquisition could happen despite threat by generic Zyvox as the demand of new and potent antibiotics is growing due to … For more detail, please read our initiation report released on 26th March, 2013 on Trius (TSRX) titled “Partnering or Buy Out = Upside”


Contact With Us
Join templatemonster at google+
Customized Research
Request Sample